Literature DB >> 10971650

Induction of neuronal death by alpha-synuclein.

A R Saha1, N N Ninkina, D P Hanger, B H Anderton, A M Davies, V L Buchman.   

Abstract

The molecular and cellular mechanisms underlying neuronal loss in neurodegenerative diseases are unclear. It is generally thought that aggregation of mutated, abnormally modified or abnormally folded proteins leads to the accumulation of extracellular, intracellular or intranuclear deposits that severely compromise cell physiology, leading to the death of the affected neurons. However, there is growing evidence that neuronal apoptosis in the absence of obvious pathological deposits could have a serious impact on the pathogenesis of neurodegenerative diseases. alpha-Synuclein has been implicated in aetiology and pathogenesis of certain neurodegenerative diseases, although the precise role of this protein in neurodegeneration is uncertain. The normal functions of alpha-synuclein and other members of the synuclein family in the development and function of the nervous system also remain elusive. Here we show that overexpression of wild-type and mutant forms of alpha-synuclein in cultured neurons, but not the closely related persyn (gamma-synuclein), causes apoptosis. These findings suggest that abnormalities of alpha-synuclein metabolism could lead to the neuronal loss occurring in certain forms of neurodegeneration before the formation of characteristic pathological lesions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971650     DOI: 10.1046/j.1460-9568.2000.00210.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  41 in total

1.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Regulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells.

Authors:  Kwang Soo Kim; Ji-Young Park; Ilo Jou; Sang Myun Park
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

3.  Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease.

Authors:  Marina S Gorbatyuk; Arseniy Shabashvili; Weijun Chen; Craig Meyers; Layla F Sullivan; Max Salganik; Jonathan H Lin; Alfred S Lewin; Nicholas Muzyczka; Oleg S Gorbatyuk
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

Review 4.  Environmental toxins and alpha-synuclein in Parkinson's disease.

Authors:  Yanying Liu; Hui Yang
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 5.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 6.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

Review 7.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

8.  Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.

Authors:  Krystyna Gołembiowska; Anna Dziubina; Magdalena Kowalska; Katarzyna Kamińska
Journal:  Neurotox Res       Date:  2009-03-05       Impact factor: 3.911

Review 9.  Mitochondria in neuroplasticity and neurological disorders.

Authors:  Mark P Mattson; Marc Gleichmann; Aiwu Cheng
Journal:  Neuron       Date:  2008-12-10       Impact factor: 17.173

10.  Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.

Authors:  Natalia Ninkina; Owen Peters; Steven Millership; Hatem Salem; Herman van der Putten; Vladimir L Buchman
Journal:  Hum Mol Genet       Date:  2009-02-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.